NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News → Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (From InvestorPlace) (Ad) Free CNCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.03▼$15.2150-Day Range$27.45▼$32.2552-Week Range$25.99▼$35.82Volume18,715 shsAverage Volume6,668 shsMarket Capitalization$17.94 millionAssets Under Management$18.00 millionDividend Yield1.91%Net Expense Ratio0.79% Stock AnalysisStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestSocial MediaStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestSocial Media Get Range Cancer Therapeutics ETF alerts: Email Address About Range Cancer Therapeutics ETFThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More Ad InvestorPlaceMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”Man who spotted Apple at $1.49 says: "Buy These 6 AI Stocks."And these will be the biggest winners CNCR ETF News HeadlinesMay 14, 2024 | seekingalpha.comIntensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology DrugMay 10, 2024 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Support Buy Rating for Context TherapeuticsMay 7, 2024 | markets.businessinsider.comRing Therapeutics Presents New Data on Anellogy™ Platform at the 27th Annual American Society of Gene & Cell Therapy ConferenceMay 6, 2024 | markets.businessinsider.comBuy Rating for CytomX Therapeutics on Promising CX-904 Probody Therapy ProspectsMarch 15, 2024 | msn.comLarge-scale study explores genetic link between colorectal cancer and meat intakeMarch 11, 2024 | markets.businessinsider.comMicrobix Unveils Test Controls for Head and Neck CancerMarch 3, 2024 | nasdaq.comThe Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKBFebruary 22, 2024 | msn.comFDA approval of cancer treatment provides new weapon against tumorsSee More Headlines Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Cancer Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings79 Fund Statistics Assets Under Management$18.00 million Average Daily Volume$19,631.40 Discount/Premium0.03% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest2,900 shs Miscellaneous Outstanding Shares1,180,000Beta1.36 Creation Unit50,000 Creation Fee$150.00 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Ad InvestorPlaceMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”Man who spotted Apple at $1.49 says: "Buy These 6 AI Stocks."And these will be the biggest winners Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.56%0.54%0.48%0.51%Other Expenses0.00%0.40%0.54%0.34%0.58%Total Expense0.79%0.72%0.70%0.58%0.70%Fee Waiver0.00%-0.53%-0.55%-0.22%-0.57%Net Expense0.79%0.60%0.60%0.54%0.58% Range Cancer Therapeutics ETF (CNCR) Holdings & ExposureTop 10 CNCR HoldingsGeron(NASDAQ:GERN)Holding Weight: 3.05%ImmunityBio(NASDAQ:IBRX)Holding Weight: 2.27%Cullinan Oncology(NASDAQ:CGEM)Holding Weight: 2.17%Acrivon Therapeutics(NASDAQ:ACRV)Holding Weight: 2.12%Deciphera Pharmaceuticals(NASDAQ:DCPH)Holding Weight: 2.08%Enliven Therapeutics(NASDAQ:ELVN)Holding Weight: 2.05%Janux Therapeutics(NASDAQ:JANX)Holding Weight: 2.01%Nuvation Bio(NYSE:NUVB)Holding Weight: 1.91%Day One Biopharmaceuticals(NASDAQ:DAWN)Holding Weight: 1.63%Revolution Medicines(NASDAQ:RVMD)Holding Weight: 1.59%CNCR Sector ExposureCNCR Industry ExposureFull Holdings Details Similar ETFsHorizon Kinetics Medical ETFNASDAQ:MEDXFirst Trust Nasdaq Pharmaceuticals ETFNASDAQ:FTXHJPMorgan Healthcare Leaders ETFNASDAQ:JDOCInvesco Nasdaq Biotechnology ETFNASDAQ:IBBQProShares UltraShort Nasdaq BiotechnologyNASDAQ:BIS CNCR ETF - Frequently Asked Questions What does CNCR invest in? Range Cancer Therapeutics ETF is a equity fund issued by Exchange Traded Concepts. CNCR focuses on health care investments and follows the Range Cancer Therapeutics Index. The fund's investments total to approximately $18.00 million assets under management. What stocks does Range Cancer Therapeutics ETF hold? CNCR invests in 79 holdings. Some of the stocks in their portfolio include Geron (GERN), ImmunityBio (IBRX), Cullinan Oncology (CGEM), Acrivon Therapeutics (ACRV), Deciphera Pharmaceuticals (DCPH), Enliven Therapeutics (ELVN), Janux Therapeutics (JANX), Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN) and Revolution Medicines (RVMD). What is the management fee for Range Cancer Therapeutics ETF? Range Cancer Therapeutics ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for CNCR is 0.79%. What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Range Cancer Therapeutics ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA), Abbott Laboratories (ABT), Alibaba Group (BABA) and Quest Diagnostics (DGX). This page (NASDAQ:CNCR) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.